F-STAR THERAPEUTICS, INC.

Eddeva B920

Babraham Research Campus

Cambridge, CB22 3AT, United Kingdom

August 19, 2021

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: David Gessert

RE: F-star Therapeutics, Inc.

Registration Statement on Form S-3

Filed August 13, 2021

File No. 333-258783

Acceleration Request

Dear Mr. Gessert:

With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of F-star Therapeutics, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Monday, August 23, 2021, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Megan Gates or William Hicks of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.

Very truly yours,

F-STAR THERAPEUTICS, INC. 

/s/ Darlene Deptula-Hicks

Darlene Deptula-Hicks

Chief Financial Officer

cc: Megan N. Gates, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

William C. Hicks, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.